Trial reportFertility and sterility2012
Effect of escitalopram on hot flash interference: a randomized, controlled trial.
Trial report in Fertility and sterility, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Menopause Strategies: Finding Lasting Answers for Symptoms and Health: Efficacy of a Selective Serotonin Reuptake Inhibitor (SSRI) for Menopausal Symptoms in Midlife Women
Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials.Iranian journal of medical sciences · 2022Pooled it
- Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review.BJOG : an international journal of obstetrics and gynaecology · 2020Pooled it
- SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials.Journal of general internal medicine · 2014Pooled it
- Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.Archives of gynecology and obstetrics · 2022Trial
- Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women.Menopause (New York, N.Y.) · 2014Trial
- Trial
- Management of menopausal hot flushes. Recommendations from the Spanish Menopause Society.European journal of obstetrics & gynecology and reproductive biology: X · 2025Review
- Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer.Prostate cancer and prostatic diseases · 2024Article
- Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations.BJOG : an international journal of obstetrics and gynaecology · 2023Article
- Lights on MsFLASH: a review of contributions.Menopause (New York, N.Y.) · 2020Review
- Management of Potential Long-Term Toxicities in Breast Cancer Patients.Current breast cancer reports · 2016Article
- Symptom clusters among MsFLASH clinical trial participants.Menopause (New York, N.Y.) · 2016Article
- Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug-Disease Interactions in the Elderly Quality Measures.Journal of the American Geriatrics Society · 2015Article
- A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients.SpringerPlus · 2015Article
- How well do different measurement modalities estimate the number of vasomotor symptoms? Findings from the Study of Women's Health Across the Nation FLASHES Study.Menopause (New York, N.Y.) · 2014Article
- Risk factors, pathophysiology, and treatment of hot flashes in cancer.CA: a cancer journal for clinicians · 2013Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveTo estimate the effect of escitalopram (10-20 mg/d) versus placebo for reducing hot flash interference in daily life and understand correlates and predictors of reductions in hot flash interference, a key measure of quality of life.
designMultisite, randomized, double-blind, placebo-controlled clinical trial.
settingMsFLASH clinical sites in Boston, Indianapolis, Oakland, and Philadelphia. PATIENT(S): A total of 205 midlife women (46% African-American) who met criteria participated. INTERVENTION(S): After baseline, women were randomized to one pill of escitalopram 10 mg/d (n = 104) or placebo (n = 101) with follow-up at 4 and 8 weeks. At week 4, those not achieving 50% fewer hot flashes were increased to two pills daily (20 mg/d or 2 placebo pills). MAIN OUTCOME MEASURE(S): The Hot Flash Related Daily Interference Scale; correlates were variables from hot flash diaries; predictors were baseline demographics, clinical variables, depression, anxiety, sleep quality, and hot flashes. RESULT(S): Compared to placebo, escitalopram significantly reduced hot flash interference by 6.0 points at week 4 and 3.4 points at week 8 more than placebo. Reductions in hot flash interference correlated with changes in hot flash diary variables. However, baseline variables did not significantly predict reductions in hot flash interference. CONCLUSION(S): Escitalopram (10-20 mg/d) for 8 weeks improves women's quality of life and this benefit did not vary by demographic, clinical, mood, sleep, or hot flash variables. CLINICAL TRIAL REGISTRATION NUMBER: NCT00894543.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.